Current updates on arrhythmia within Timothy syndrome: genetics, mechanisms and therapeutics.

Timothy syndrome is a very rare genetic condition that causes dangerous heart rhythm problems and webbed fingers or toes. It's caused by problems with calcium channels in the heart. Current treatments include various heart medications and pacemakers. Researchers are exploring new approaches using stem cells to better understand and treat this serious condition.

This comprehensive review examines Timothy syndrome (TS), a rare genetic disorder affecting the cardiac L-type voltage-gated calcium channel, causing life-threatening heart rhythm abnormalities and physical features like webbed fingers/toes. The review covers genetic mutations, molecular mechanisms of calcium channel dysfunction, and resulting arrhythmias. Current treatments include calcium channel blockers, beta-blockers, sodium channel blockers, multichannel inhibitors, and pacemakers. The authors highlight promising future research using patient-specific induced pluripotent stem cells for developing new therapies.

The review provides updated understanding of TS genetics, pathophysiology, and therapeutic approaches for managing this devastating condition.

The review consolidates current understanding of Timothy syndrome management, highlighting multiple therapeutic options for cardiac complications. The emphasis on patient-specific stem cell research suggests future personalized treatment possibilities, though current management relies on conventional cardiac medications and devices.

This is a narrative review without systematic methodology or quality assessment of included studies. No new empirical data is presented, and the review relies on existing literature without meta-analysis.

Timothy syndrome (TS), characterised by multiple system malfunction especially the prolonged corrected QT interval and synchronised appearance of hand/foot syndactyly, is an extremely rare disease affecting early life with devastating arrhythmia. In this work, firstly, the various mutations in causative geneencoding cardiac L-type voltage-gated calcium channel (LTCC), regard with the genetic pathogeny and nomenclature of TS are reviewed. Secondly, the expression profile and function ofgene encoding Ca1.2 proteins, and its gain-of-function mutation in TS leading to multiple organ disease phenotypes especially arrhythmia are discussed. More importantly, we focus on the altered molecular mechanism underlying arrhythmia in TS, and discuss about how LTCC malfunction in TS can cause disorganised calcium handling with excessive intracellular calcium and its triggered dysregulated excitation-transcription coupling.

In addition, current therapeutics for TS cardiac phenotypes including LTCC blockers, beta-adrenergic blocking agents, sodium channel blocker, multichannel inhibitors and pacemakers are summarised. Eventually, the research strategy using patient-specific induced pluripotent stem cells is recommended as one of the promising future directions for developing therapeutic approaches. This review updates our understanding on the research progress and future avenues to study the genetics and molecular mechanism underlying the pathogenesis of devastating arrhythmia within TS, and provides novel insights for developing therapeutic measures.